Rheumatoid arthritis treatment: The earlier the better to prevent joint damage

RMD Open

Volumn 1, Issue , 2015, Pages

  Monti, Sara ^a   Montecucco, Carlomaurizio ^a   Bugatti, Serena ^a   Caporali, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018192803     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2015-000057     Document Type: Review

References (37)

1. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
3. Mäkinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34:316-21.
4. De Cock D, Vanderschueren G, Meyfroidt S, et al. Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice. Clin Rheumatol 2014;33:125-30.
5. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
6. Möttönen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
7. Van Nies J a. B, Tsonaka R, Gaujoux-Viala C, et al. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. Ann Rheum Dis 2015; epub ahead of print.
8. Gremese E, Salaffi F, Bosello SL, et al. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013;72:858-62.
9. Nell VPK, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatol Oxf Engl 2004;43:906-14.
10. Van der Linden MPM, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010;62:3537-46.
11. Van Nies J a. B, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014;73:861-70.
12. Lukas C, Combe B, Ravaud P, et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 2011;63:1804-11.
13. Cader MZ, Filer A, Hazlehurst J, et al. Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 2011;70:949-55.
14. Van der Heijde D, van der Helm-van Mil AHM, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/ EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013;72:479-81.
15. Mueller RB, Schiff M, Kaegi T, et al. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. Clin Rheumatol 2015;34:51-9.
16. Emad Y, Anbar A, Abo-Elyoun I, et al. In palindromic rheumatism, hand joint involvement and positive anti-CCP antibodies predict RA development after 1 year of follow-up. Clin Rheumatol 2014;33:791-7.
17. Pincus T, Castrejón I. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis 2013. 2013;71 Suppl 1:S33-40.
18. Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 2012;71:845-50.
19. Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
20. Kievit W, Fransen J, de Waal Malefijt MC, et al. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatol Oxf Engl 2013;52:1500-8.
21. Sakellariou G, Scirè CA, Verstappen SMM, et al. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 2013;72:245-9.
22. Caporali R, Conti F, Covelli M, et al. Treating rheumatoid arthritis to target: an Italian rheumatologists' survey on the acceptance of the treat-to-target recommendations. Clin Exp Rheumatol 2014;32:471-6.
23. Kuriya B, Xiong J, Boire G, et al. Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis-results from the Canadian Early Arthritis Cohort (CATCH). J Rheumatol 2014;41:2161-6.
24. Schipper LG, Fransen J, den Broeder AA, et al. Time to achieve remission determines time to be in remission. Arthritis Res Ther 2010;12:R97.
25. Atzeni F, Antivalle M, Pallavicini FB, et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8:431-7.
26. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
27. Todoerti M, Scirè CA, Boffini N, et al. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci 2010;1193:139-45.
28. Rantalaiho V, Korpela M, Laasonen L, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010;12:R122.
29. Bakker MF, Jacobs JWG, Welsing PMJ, et al. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011;70:1099-103.
30. Kuriya B, Arkema EV, Bykerk VP, et al. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010;69:1298-304.
31. Van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46.
32. Keystone EC, Haraoui B, Guérette B, et al. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. J Rheumatol 2014;41:235-43.
33. Heimans L, Wevers-de Boer KVC, Koudijs KKM, et al. Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. Arthritis Res Ther 2013;15:R173.
34. Myasoedova E, Chandran A, Ilhan B, et al. The role of rheumatoid arthritis(RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis 2015. Published Online First 30 Jan 2015. doi:10.1136/annrheumdis-2014-206411.
35. Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011;70:812-7.
36. Cavagna L, Boffini N, Cagnotto G, et al. Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediators Inflamm 2012;2012:147354.
37. Scirè CA, Lunt M, Marshall T, et al. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2014;73:1677-82.